Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer.
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...
3don MSN
A new nanorobot designed to improve immune cell recognition could help treat colorectal cancer
Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA priority ...
The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback